Norwegian entrance in EU technology network

The Norwegian University of Science and Technology joins the European Science Business Network of prominent European research institutions.

Vitrolife wants to acquire Medicult

The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.

SDU professor helps EU

Mette Præst Knudsen from the University of Southern Denmark, SDU, has been appointed as an expert member in an EU politics group.

New CEO to Swedish Tillotts Pharma

The Swiss company Tillotts Pharma's newly established Swedish organisation has appointed a CEO from Bayer Scandinavia.

New faces in Pronova Biopharma team

The Norwegian company Pronova Biopharma has recently changed the management team structure.

New Nordic nutrition collaboration

Scandinavian Clinical Nutrition has recently signed a unique Nordic distribution agreement.

New Nordic biotech company

The Swiss biotech company Tillots Pharma opens a office in Stockholm, which will be run under private management.

Swedish cancer therapy granted

Pledpharma, Linköping University and Ryhov County Hospital receive a research grant from the Research Council FORSS to conduct clinical studies in cancer patients.

Sales Representative, Applied Biosystems

New management at Øresund

The Øresund University has recently appointed a new director and a new Chairman.

New firm based on SLU research

Four researchers at the Swedish University of Agricultural Sciences, SLU, has recently founded a new nanotech company.

Bring talent to those in need

Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.

A platform for dialogue

As a step towards connecting the life science industry in Denmark, Biologue was founded three years ago with 10 member companies. Today, the network has 40 members and a very busy event calender.

Time to save for survival

The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.